Abstract
US companies Fluidigm Corporation (San Francisco, CA, USA) and Axon Instruments Inc. (Union City, CA, USA) are collaborating on a new venture to develop microfluidic chips that can capture and manipulate individual cells, reports Chemweb.com (6 July). The new chips will allow drug discovery researchers to directly study drug–target interactions in a cellular environment. Fluidigm's chip technology can isolate a single eukaryotic cell and change its local environment without damaging it, and the link-up with Axon could lead to new high-throughput screening technology for faster drug discovery. MJD
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
